NP311301.RAPKrmJtoZaAofdMFxjkBgjfMkqiwkolhhREHYjIfa-do
type: Nanopublication
has assertion: NP311301.RAPKrmJtoZaAofdMFxjkBgjfMkqiwkolhhREHYjIfa-do130 assertion
has provenance: NP311301.RAPKrmJtoZaAofdMFxjkBgjfMkqiwkolhhREHYjIfa-do130 provenance
has publication info: NP311301.RAPKrmJtoZaAofdMFxjkBgjfMkqiwkolhhREHYjIfa-do130 publicationInfo
created: 2016-05-13T12:44:06+02:00
rights: http://opendatacommons.org/licenses/odbl/1.0/
rights holder: IBIGroup
subject: SIO_000983
used data: disgenetv3.0rdf
authored by: http://orcid.org/0000-0001-5999-6269
authored by: http://orcid.org/0000-0002-7534-7661
authored by: 0000-0002-9383-528X
authored by: http://orcid.org/0000-0003-0169-8159
authored by: http://orcid.org/0000-0003-1244-7654
created by: http://orcid.org/0000-0003-0169-8159
version: v4.0.0.0

NP311301.RAPKrmJtoZaAofdMFxjkBgjfMkqiwkolhhREHYjIfa-do130 assertion
type: Assertion
description: [To investigate the relationship between HPC2/ELAC2 and prostate cancer risk, we performed the following analyses: (1) a linkage study of six markers in and around the HPC2/ELAC2 gene at 17p11 in 159 pedigrees with hereditary prostate cancer (HPC); (2) a mutation-screening analysis of all coding exons of the gene in 93 probands with HPC; (3) family-based and population-based association study of common HPC2/ELAC2 missense variants in 159 probands with HPC, 249 patients with sporadic prostate cancer, and 222 unaffected male control subjects.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine.
evidence: DisGeNET evidence - LITERATURE
SIO_000772: http://identifiers.org/pubmed/11254448
was generated by: ECO_0000203

befree-2016
imported on: 2016-02-19

DisGeNET evidence - LITERATURE
type: ECO_0000212
comment: Gene-disease associations inferred from text-mining the literature.

disgenetv3.0rdf
version: v4.0.0